FORM 10-Q
                              
             SECURITIES AND EXCHANGE COMMISSION
                    Washington, DC  20549
                              
   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
               SECURITIES EXCHANGE ACT OF 1934
                              
        For the quarterly period ended March 31, 1999
                              
               Commission File Number  0-23666


                        TRIPOS, INC.
   (Exact Name of Registrant as Specified in its Charter)
                              
                     Utah               43-1454986
     (State or Other Jurisdiction of    (I.R.S. Employer
 Incorporation or Organization)          Identification No.)

                   1699 South Hanley Road
                 St. Louis, Missouri  63144
    (Address of Principal Executive Offices and Zip Code)
                              
                              
                       (314) 647-1099
    (Registrant's Telephone Number, Including Area Code)
                              
                              

Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing
requirement for the past 90 days.

Yes  X              No

Number of shares outstanding of the issuer's Common Stock, par
value $.01 per share, as of March 31, 1999:  3,259,647 shares.



                              
                              
                      TABLE OF CONTENTS
                              
                              
                              
PART I  FINANCIAL INFORMATION,                            Page
   Item 1.  Financial Statements (Unaudited)

    Consolidated Balance Sheets at
        March 31, 1999 and December 31, 1998               3

    Consolidated Statements of Operations
        for Three Months Ended March 31, 1999 
        and March 31, 1998                                 4

    Consolidated Statements of Cash Flows for Three Months
        Ended March 31, 1999 and March 31, 1998            5

    Notes to Consolidated Financial Statements             6



Item 2. Management's Discussion and Analysis of Financial
  Condition and Results of Operations                      8


PART II  OTHER INFORMATION                                12

SIGNATURES                                                13

                           PART I
                    FINANCIAL INFORMATION

Item 1.  Financial Statements.

                    CONSOLIDATED BALANCE SHEETS
                       (In thousands)
                         (Unaudited)
                                         Mar. 31,      Dec. 31,
                                           1999          1998
                            ASSETS
  Current Assets:                                   
                                                              
     Cash and cash equivalents             $ 2,393     $ 1,774
     Accounts receivable                    10,129      12,451
     Inventory                               2,292       2,389
     Prepaid expenses                          818       1,278
     Deferred income taxes                     226         242
  Total current assets                      15,858      18,134
                                                              
    Notes Receivable-trade                   2,539       2,304
    Notes Receivable-other                     881         863
    Property and equipment, less                              
       Accumulated depreciation             12,420      11,076
    Capitalized development costs, net         841         877
    Goodwill, net of amortization            1,123       1,147
    Investment in unconsolidated 
      affiliate                              2,367       1,982
     Other, net                                418         427
                                                              
  Total assets                            $ 36,447    $ 36,810
                                                              
             LIABILITIES AND SHAREHOLDERS' EQUITY
  Current Liabilities:                                        
  Current portion of long-term debt                                
   to be refinanced and capital leases    $    327    $     328
  Accounts payable                           1,141          827
  Accrued expenses                           1,484        2,858
  Deferred revenue                           5,901        5,005
  Total current liabilities                  8,853        9,018
                                                              
  Long-term portion of capital leases          180          226
  Long-term debt to be refinanced             6,145       5,289
  Long-term deferred revenue                  2,238       2,303
  Deferred income taxes                         442         465
                                                              
  Shareholders' equity :                                      
   Common Stock                                  33          33
   Additional paid-in capital                17,998      17,980 
   Retained earnings                            781       1,269
   Other comprehensive income                  (223)        227
  Total shareholders' equity                 18,589      19,509
                                                              
  Total liabilities and                    $ 36,447    $ 36,810
  shareholders' equity
                                                              
See accompanying notes.
                                                              
Item 1.  Financial Statements (cont'd)


                 CONSOLIDATED STATEMENTS OF OPERATIONS
                 (In thousands, except per share data)
                              (Unaudited)
                                         Three Months Ended
                                        Mar. 31,       Mar. 31,
                                          1999           1998
  Net sales:                                       
    Software licenses                      $ 1,816     $ 1,986
    Support                                  2,057       1,894
    Accelerated discovery services           1,363       1,190
    Hardware                                   919       1,114
  Total net sales                            6,155       6,184
                                                   
  Operating costs and expenses:
    Cost of sales                            1,870       2,168
    Sales and marketing                      2,347       2,334
    Research and development                 1,747       1,352
    General and administrative               1,096         871
  Total costs and expenses                   7,060       6,725
                                                   
  Loss from operations                        (905)       (541)
                                                              
  Other income, net                            120          69
                                                              
  Loss before income taxes                    (785)       (472)
                                                              
  Income tax benefit                          (299)       (170)
                                                   
  Net loss                                  $ (486)    $  (302)
                                                   
  Basic and diluted loss per share          $ (0.15)   $ (0.10)
  Basic and diluted weighted                                  
    average number of shares                  3,257      3,176
                                                   
  See accompanying notes.

                              
           Item 1.  Financial Statements (cont'd)
                              
            CONSOLIDATED STATEMENTS OF CASH FLOWS
                       (In Thousands)
                         (Unaudited)
                                         Three Months Ended
                                         Mar. 31,      Mar. 31,
                                           1999          1998
  Operating activities:                             
  Net loss                                 $ (486)    $ (302)
  Adjustments to reconcile net loss                          
   to net cash provided by operating
   activities:
     
  Depreciation of property and equipment      310        188
  Amortization of capitalized                             
    development costs and goodwill            167        484
  Deferred income taxes                        (7)       (60)
                                                    
  Change in operating assets and                    
   liabilities:
    Accounts receivable                     1,928        375
    Notes receivable-trade                   (235)      (128)
    Inventories                                21         -   
    Prepaid expenses and other                       
     current assets                           474       (257)
    Accounts payable and accrued expenses    (508)      (707)
    Deferred revenue                        1,013      1,833
  Net cash provided by operating activities 2,677      1,426
                                                    
  Investing activities:                                      
    Net purchases, sales, and maturities                 
     of investments                            -         499
    Notes receivable-other                    (18)       (18)
    Purchases of property and equipment    (1,878)      (198)
    Capitalized development costs            (143)       (46)
    Acquisition, including investment in                         
      unconsolidated affiliates              (385)        -
    Net cash provided by (used in)                
      investing activities                 (2,424)       237                 

  Financing activities:                             
    Stock issuance pursuant to stock plans     18         50
    Issuance of long-term debt                845        (48)
  Net cash provided by financing activities   863          2
                                                    
  Effect of foreign exchange rate changes                        
   on cash and cash equivalents              (497)        88
                                                    
  Net increase in cash and cash equivalents   619      1,753
                                                    
  Cash and cash equivalents at               
   beginning of period                      1,774      5,277
  Cash and cash equivalents at end         
   of period                               $2,393     $7,030

See accompanying notes.

Item 1.  Financial Statements (cont'd)
                              
    NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
            (In thousands, except per share data)
                              

(1)  Summary of significant accounting policies

     (a)  Organization

      Tripos,  Inc. (the "Company") delivers science,  tools  and
analysis   services  that  advance  customers'   creativity   and
productivity  in pharmaceutical, agrochemical, biotechnology  and
related  research industries worldwide.  The Company  is  also  a
value-added reseller of third party hardware products required to
operate  its  software products.  A substantial  portion  of  the
Company's  business  is conducted with pharmaceutical  companies,
however,  the  Company  is  not  economically  dependent  on  any
customer on an ongoing basis.

     (b)  Basis of Presentation

     The accompanying unaudited consolidated financial statements
have   been  prepared  in  accordance  with  generally   accepted
accounting principles for interim financial information and  with
the  instructions to Form 10-Q and Article 10 of Regulation  S-X.
Accordingly,  they  do  not include all of  the  information  and
footnotes  required  by generally accepted accounting  principles
for complete financial statements.  In the opinion of management,
all   normal   recurring  adjustments  necessary   for   a   fair
presentation  of  such financial statements have  been  included.
Operating results for the three month period ended March 31, 1999
are  not  necessarily  indicative of  the  results  that  may  be
expected for the year ending December 31, 1999.

(2)  Income Taxes

      The  provision  for  income taxes  is  computed  using  the
liability  method.   The  primary  difference  between  financial
statement  and taxable income results from the use  of  different
methods  of  computing  capitalized  development  costs,  accrued
vacation and customer deposits.

(3)  Comprehensive Income

      The components of comprehensive income, net of related tax,
for the three-month periods ended March 31, 1999 and 1998 are  as
follows:

                                              1999         1998
  Net loss                                 $ (486)      $ (302)
  Foreign currency translation adjustments   (450)          80    
  Comprehensive loss                       $ (936)      $ (222)



The components of accumulated other comprehensive income, net  of
related  tax,  at  March 31, 1999 and December 31,  1998  are  as
follows:
                                            1999         1998
  Foreign currency translation           $ (223)        $ 227
  adjustments
                                                             
  Accumulated other comprehensive        $ (223)        $ 227
  income (loss)


(4)     Earnings Per Share

The  following table sets forth the computation of  basic  and
diluted  earnings per share for the quarters ended  March  31,
1999 and 1998.
                                                1999       1998
Numerator:                                             
  Numerator for basic and diluted earnings                     
   per share-net loss                         $ (488)    $ (302)
Denominator:                                                   
  Denominator for basic earnings per share-                    
     weighted average shares                   3,257      3,176
  Effect of dilutive securities:  Employee                     
  stock options  Note A                           -          -
  Denominator for diluted earnings per                         
   share-adjusted weighted average shares 
   and assumed conversions                     3,257      3,176
Basic loss per share                          $(0.15)    $(0.10)
Diluted loss per share                        $(0.15)    $(0.10)

Note  A:   Employee stock options to purchase  shares  of  the
Company's common stock were not included in the March 31, 1999
computation of diluted earnings per share because  the  effect
would  have  been  anti-dilutive.  For additional  disclosures
regarding  earnings per share, see the notes to the  Company's
1998 consolidated financial statements in its Form 10-K.

(5)  Inventory

     The  Company  maintains  a physical  inventory  of  chemical
compound  libraries  in  various  states  of  completion.   Costs
associated with the manufacture of compounds are calculated using
the standard cost method and are carried at the lower of cost  or
market.  Compounds that are acquired from third parties are  also
carried at the lower of cost or market.  Finished Goods inventory
may periodically contain costs of computer hardware that has been
acquired for resale to the Company's customers.


                                    March 31,  December 31,
                                         1999       1998

       Raw materials..........            $43        $44
       Work in process..........          589      1,764
       Finished goods............       1,660        581
                                       $2,292     $2,389


(6)  Long Term Debt

     At  March  31, 1999 the Company maintained a $12,000  Credit
Agreement  and a mortgage note with a bank.  The Credit Agreement
and  mortgage note required the Company to meet certain financial
covenants,  including  various coverage  ratios  and  a  debt  to
capitalization ratio.  As of March 31, 1999, the Company  was  in
violation of one covenant for that quarterly reporting period.

     On  April  30, 1999, the Company entered into a  new  credit
facility  with  a  bank, which refinanced  the  existing  $12,000
Credit Agreement and the mortgage note.  The new Credit Agreement
is  for  a  total of $15,320 which is broken into three  separate
credit  facilities: a $3,320 secured real estate mortgage, $4,000
three-year secured term loan, and an $8,000 three-year  revolving
line  of  credit.   The  Credit Agreement  is  collateralized  by
substantially all of the Company's U.S. assets and  stock pledges
for  the  Company's  U.S. and foreign subsidiaries.   The  credit
facility  also  requires  the Company to meet  certain  financial
covenants, including various coverage ratios. The Company expects
to meet these new covenant requirements during 1999.

(7)  Recent Accounting Pronouncements

       In  June  1998,  the Financial Accounting Standards  Board
issued  Statement No. 133, "Accounting for Derivative Instruments
and  Hedging  Activities" ("FAS 133"), which is  required  to  be
adopted  in years beginning after June 15, 1999.  FAS 133 permits
early  adoption as of the beginning of any fiscal  quarter  after
its  issuance.   The Company expects to adopt the  new  Statement
effective  January 1, 2000.  FAS 133 will require the Company  to
recognize  all  derivatives on the balance sheet at  fair  value.
The  Company has not yet determined what the effect FAS 133  will
be on the earnings and financial position of the Company.

Item  2.   Management's  Discussion  and  Analysis  of  Financial
Condition and Results of Operations

Overview

      Tripos, Inc. is a leader in discovery services, informatics
and  products for life science organizations worldwide.   Tripos'
current  proprietary  technologies  and  strategic  relationships
expand  its  reputation in computational chemistry for  efficient
pharmacological activity prediction and analysis, a major  factor
in  customers'  cost-effective new  product  success.   Based  on
scientific expertise in these areas as well as a worldwide  sales
and marketing organization, Tripos expanded its business model in
1997.   The  Company  now  offers  the  following  products   and
services:   software,  software consulting  services,  technology
transfer,  screening libraries, and contract discovery  research.
The  Company  continues to be a reseller of third party  hardware
products   that  are  compatible  with  the  Company's   software
products.

     The Company's revenues and expenses can vary from quarter to
quarter depending upon, among other things, the Company's ability
to  produce  compound libraries in a timely manner,  the  capital
expenditure  budgets  of  its customers,  lengthy  sales  cycles,
market  acceptance  of  new  products and  enhanced  versions  of
existing products, the timing of new product introductions by the
Company  and  other vendors, changes in pricing policies  by  the
Company,  partners  and  other vendors, and  changes  in  general
economic  and competitive conditions.  In addition,  the  Company
may chose to negotiate a long-term software license contract that
may,  subject to certain rules of SOP 97-2, be recognized ratably
over  the  life  of the contract. A substantial  portion  of  the
Company's revenues for each quarter is attributable to a  limited
number of orders and tends to be realized toward the end of  each
quarter.  Thus, even short delays or deferrals of sales near  the
end  of  a  quarter  can  cause quarterly  results  to  fluctuate
substantially.  The Company typically experiences  greater  gross
margins  on software licenses, contract research, custom software
development  and  chemical  compound  sales  than  on  sales   of
hardware.  The Company's profitability depends in part on the mix
of its revenue components and not necessarily on total revenues.

Year 2000 Issues

The  Company  provides software licenses that are  activated  and
remain  active based on date and time of the computer  where  the
software resides. Tripos products sold to its customers are  Year
2000 compliant.  The Company relies on the hardware suppliers  to
address any and all Year 2000 issues  and  provide letters of 
compliance to the  Company.   The total  dollar amount that the 
Company estimates will be spent  to remediate  its Year 2000 issues 
will not be material  and  should not  affect future financial results 
of operations, liquidity  or capital resources.

     The  Company  has no software used for internal  processing,
other  than  its  software products that are  already  Year  2000
compliant that are more than three years old.  When written, this
software was Year 2000 compliant.  The Company has been verifying
its  Year  2000  compliance throughout 1998 and  into  1999.   In
addition to informal testing and purchases of Year 2000 compliant
software  and  equipment, the Company started  development  of  a
formal  plan in October 1998.  The second phase of the  planning,
which  will  be  completed in May 1999 includes  a  full  written
description of potential problems.  The third phase is  follow-up
documentation,  which  includes a  written  description  of  each
solution  and work-around as well as the testing plan to validate
a  workable  solution.   The  third  phase  is  estimated  to  be
completed  in early June 1999.  Immediately following  the  third
phase  will  be  the validation of the proposed solutions.   This
fourth  phase is estimated to be completed by July 15, 1999.   In
July 1999, the Company will implement the solutions.  Finally, in
September  1999, the Company will fully implement the plan.   The
implementation  will  mean that a) all computers  are  Year  2000
compliant,  or  b)  computers not Year 2000  compliant  will  not
affect  the  company's ability to conduct  business,  and  c)  no
changes will be made to already validated systems unless adequate
testing (re-validation) is performed.

     Tripos  is  dependent  upon  many  third  parties  for   the
operation  of the business.  These include hardware and  software
suppliers,  suppliers of raw materials to the compound  business,
and suppliers of business services such as payroll and accounting
services.   To  date, the Company is not aware  of  any  external
agent  with  a Year 2000 issue that would materially  impact  the
Company's results of operations, liquidity, or capital resources.
The  Company  will make appropriate contingency  plans  should  a
vendor  or supplier report that it is not Year 2000 compliant  or
will not be by January 1, 2000. However, the Company has no means
of  ensuring that external agents will be Year 2000  ready.   The
inability  of  external  agents  to  complete  their  Year   2000
resolution  process in a timely fashion could  materially  impact
the Company.  The effect of non-compliance by external agents  is
not determinable.

     The  costs  of  the Year 2000 project are  included  in  the
Company's annual software and hardware budget.  These amounts  do
not  differ  materially  from those costs  experienced  in  prior
periods.  Acquisitions of new hardware are dealt with as part  of
the ordinary capital purchase process and were not accelerated by
the  Year 2000.  In addition, the Company has allocated funds for
the  purchase of Year 2000 compliance testing software, estimated
to  be  $7,000.   Other  costs will be  expensed  or  capitalized
according  to  established Company procedures.   At  present,  no
material  costs are anticipated, and during the periods presented
there   have  been  no  costs  incremental  to  normal  operating
activities.

     Management  of  the  Company believes it  has  an  effective
program  in  place  to resolve the Year 2000 issue  in  a  timely
manner.   As  noted above, the Company has not yet completed  all
necessary phases of the year 2000 program.  In the event that the
Company  does  not  complete any additional phases,  the  Company
would be unable to take customer orders for compounds, issue keys
to  activate  software,  manufacture or  ship  products,  invoice
customers or collect payments.  The amount of lost revenue cannot
be reasonably estimated at this time.

     The  Company  is currently assessing its contingency  plans.
These contingency plans will be developed as part of the remedial
steps taken in the second and third quarter of 1999.

     Except   for   the  historical  information  and  statements
contained  in  Management's Discussion and Analysis of  Financial
Condition  and  Results of Operations ("MD&A"), the  matters  and
items contained in this document, including MD&A, contain certain
forward-looking statements that involve uncertainties and  risks.
The  Company's future results could differ materially from  those
discussed  in  this  document.   Factors  that  could   cause   a
contribution  to such differences, include, but are  not  limited
to, those presented in the Company's Form 10-K for the year ended
December 31, 1998.

Results of Operations

      Net  sales for the first quarter of 1999 and 1998 were $6.2
million.   The  Company  experienced  increases  in  support  and
accelerated  discovery services revenue offset  by  decreases  in
software license and hardware sales in the quarter.

     For the three months ended March 31, 1999, software licenses
sales decreased slightly to $1.8 million.  Software license sales
are  historically  volatile  in the  first  quarter  as  customer
capital  budgets are finalized and apportioned.  Support revenues
increased 8.6% to $2.1 million compared to the first three  month
period  in 1998.  The increase in support revenue is due  to  the
increase in long term token license sales.  The Company allocates
a portion of the sale to support which is recognized ratably over
the  life  of  the  agreement.   Accelerated  Discovery  Services
("ADS") sales accounted for $1.4 million in the first quarter  of
1999  and $1.2 million in the same period in 1998.  This increase
in  ADS business was expected due to shipment of backlog from the
prior  quarter. Hardware sales decreased by 17.5% to $.9  million
for the first quarter 1999.  This decrease is attributable to the
occurrence  of  several large orders in the first  quarter  1998.
Sales to existing customers represent 91% of total net sales  for
the three-month period ending March 31, 1999.

      Net  sales  for the Company's activities outside  of  North
America  represented  approximately 58.5%  for  the  first  three
months  of  1999 compared to 38.9% for the same period  in  1998.
Net sales in Europe increased 60.6% for the first three months of
1999  compared to 1998 and accounted for 48.4% and 30.1% of   net
sales for the  three-month periods  in  1999 and 1998,  respectively.  
Net sales in the Pacific  Rim,  principally Japan, increased 15.0% 
compared to the first three months of 1998 and  accounted for 10.1% 
and 8.8% of net sales for the respective periods.

      Cost  of sales for the three-month period ending March  31,
1999  decreased 13.7%  compared to the same period in 1998.  Cost
of  sales was $1.9 million and $2.2 million for the first quarter
of 1999 and 1998, respectively.  This change was due to decreased
costs directly related to lower sales of hardware and software as
well  as  the decrease in costs of discovery compounds  over  the
prior  year.  Cost of sales as a percent of net sales  was  30.4%
and   35.1%  for  the  three-month  periods  in  1999  and  1998,
respectively.

      Gross  profit margin percentage for the first quarter  1999
increased  to  69.6% from 64.9% of total net sales in  the  first
quarter of 1998.  This increase in gross profit percentage is due
to the decreases in cost of sales described above.

     Sales  and  marketing expenses remained  the  same  at  $2.3
million  for the three-month period in 1999 and 1998.  Sales  and
marketing  expenses as a percentage of net sales were  38.1%  and
37.7% for the three-month periods in 1999 and 1998, respectively.

      Research and development expenses increased to $1.7 million
from  $1.4  million and represented 28.4% and 21.9% of net  sales
for  the three-month periods in 1999 and 1998, respectively.  The
increase  in  expenses as a percentage of net sales reflects  the
decrease in the amount of capitalized costs as the Company  moves
from   long-term  software  development  cycles  to  shorter-term
development  cycle  for  web-based  software  applications,   the
increase  in chemistry staff at Tripos Receptor Research,  shared
costs  for the collaborations with Arena Pharmaceuticals and  the
Wolfson  Institute, and an increase in staff and  facilities  for
software consulting programmers.

     General and administrative expenses increased 25.9% to  $1.1
million for the first quarter of 1999 compared to $0.9 million in
1998,  and  represent  17.8%  and 14.1%  of  net  sales  for  the
respective periods.  The increase in G & A expenses in the period
is due to the addition of Tripos Receptor Research administrative
staff.
     
      Other income (expense) increased from $69,000 of income for
the  first  quarter  in  1998  to  $120,000  of  income  for  the
comparable  period  in  1999.  This change  was  due  to  foreign
currency transaction losses in the prior period partially  offset
by  a decrease in interest income from investments in the current
period.

      Income tax benefit was $299,000 for the three-month  period
in  1999, which represents an effective tax rate of 38%, compared
to  an  income tax benefit of $170,000 for the first  quarter  of
1998, an effective rate of 36%.  The rates reflect the change  in
the   relative  weight  of  the  Company's  earnings  and  losses
including   those  from  foreign  subsidiaries.   The   Company's
effective  tax  rate for the three months ended  March  31,  1999
reflects  an  increase to approximate the expected effective  tax
rate for the year ending December 31, 1999.

Liquidity, Capital Resources and Capital Commitments

     For the three-month period ending March 31, 1999, a decrease
in  accounts  receivable of $1.9 million, along with depreciation
and  amortization  and an increase in deferred  revenue  of  $0.3
million, $0.2 million and $1.0 million, respectively, were offset
by  a  decrease in accounts payable and accrued expenses of  $0.5
million,  an increase in prepaid expenses of $0.5 million  and  a
net  loss  of  $0.5  million resulted in  net  cash  provided  by
operations  of $2.7 million.  For the same period  in  1998,  net
cash  provided  by operations was $1.4 million primarily  due  to
decreases in accounts and notes receivable of $0.2 million  along
with  net  income,  depreciation, amortization and  increases  in
deferred  revenue  of $0.3 million, $0.2 million,  $0.5  million,
$1.8  million  respectively, which were offset by a  decrease  in
accounts  payable  and accrued expenses of $0.7  million  and  an
increase  in prepaid expenses of $0.3 million.  Notes receivable-
trade  represent the long-term portion of revenue generated  from
the  Company's sales of extended access contracts to its software
technologies.

      Investments  of  $1.9  million in property  and  equipment,
mainly  attributable  to the increased investment  in  production
facilities  at Tripos Receptor Research, and an increase  in  the
Arena  investment  of  $0.4  million resulted  in  cash  used  by
investing  activities of approximately $2.4 million in the  first
three months of 1999.

     The  Company believes that current working capital  of  $7.0
million,  together with continued cash flow from  operations  and
the  $12 million line of credit, will be adequate to fund  short-
term liquidity requirements including investment in research  and
development, capital purchases and any other commitments  in  the
upcoming year.


                           PART II
                      OTHER INFORMATION
                              
Item 1.   Legal Proceedings

          The Company is not a party to any material litigation
           and is not aware of any threatened material litigation.

Item 2.   Changes in Securities

          None

Item 3.   Defaults upon Senior Securities

          None

Item 4.   Submission of Matters to a Vote of Security Holders

          None

Item 5.   Other Information

          None

Item 6.   Exhibits and Reports on Form 8-K

          (a) List of Exhibits

               27   Financial Data Schedule

          (b) No reports on Form 8-K were required to be filed
            during the three months ended March 31, 1999.




                        TRIPOS, INC.
                         SIGNATURES
                              
      Pursuant to the requirements of the Securities Exchange Act
of  1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.

                              TRIPOS, INC.


Date:          May 12, 1999   /s/ John P. McAlister
                              President and
                              Chief Executive Officer


Date:          May 12, 1999   /s/ Colleen A. Martin
                              Chief Financial Officer, Secretary